Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapyGRAZIANO, F; RUZZO, A; MASI, G et al.British journal of cancer. 2008, Vol 99, Num 5, pp 716-721, issn 0007-0920, 6 p.Article

High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practiceSANTINI, D; SPOTO, C; CARAGLIA, M et al.Annals of oncology. 2010, Vol 21, Num 7, issn 0923-7534, p. 1565Article

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patientsCREA, F; FORNARO, L; RONZONI, M et al.Annals of oncology. 2012, Vol 23, Num 5, pp 1207-1213, issn 0923-7534, 7 p.Article

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapyCATALANO, V; LOUPAKIS, F; ALESSANDRONI, P et al.British journal of cancer. 2009, Vol 100, Num 6, pp 881-887, issn 0007-0920, 7 p.Article

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerLOUPAKIS, F; CREMOLINI, C; ANTONIOTTI, C et al.European journal of cancer (1990). 2014, Vol 50, Num 1, pp 57-63, issn 0959-8049, 7 p.Article

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)FORNARO, L; LONARDI, S; ZANIBONI, A et al.Annals of oncology. 2013, Vol 24, Num 8, pp 2062-2067, issn 0923-7534, 6 p.Article

Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patientsVINCENZI, B; GALLUZZO, S; RUZZO, A et al.Annals of oncology. 2011, Vol 22, Num 5, pp 1141-1146, issn 0923-7534, 6 p.Article

Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal CancerMANZONI, M; ROVATI, B; DANOVA, M et al.Oncology. 2010, Vol 79, Num 3-4, pp 187-196, issn 0030-2414, 10 p.Article

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patientsSCARTOZZI, M; BEARZI, I; LABIANCA, R et al.British journal of cancer. 2011, Vol 104, Num 11, pp 1786-1790, issn 0007-0920, 5 p.Article

A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancerFORNARO, Lorenzo; MASI, G; DEL TACCA, M et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 5, pp 965-969, issn 0344-5704, 5 p.Article

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancerVASILE, E; MASI, G; ANTONUZZO, A et al.British journal of cancer. 2009, Vol 100, Num 11, pp 1720-1724, issn 0007-0920, 5 p.Article

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerLOUPAKIS, F; RUZZO, A; FLORIANI, I et al.British journal of cancer. 2009, Vol 101, Num 4, pp 715-721, issn 0007-0920, 7 p.Article

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancerMASI, G; MARCUCCI, L; CUPINI, S et al.Annals of oncology. 2006, Vol 17, Num 8, pp 1249-1254, issn 0923-7534, 6 p.Article

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumabLOUPAKIS, F; SCHIRRIPA, M; MARMORINO, F et al.British journal of cancer. 2013, Vol 108, Num 12, pp 2549-2556, issn 0007-0920, 8 p.Article

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan―cetuximabSCARTOZZI, M; GIAMPIERI, R; LOUPAKIS, F et al.Annals of oncology. 2012, Vol 23, Num 7, pp 1706-1712, issn 0923-7534, 7 p.Article

Prognosis of mucinous histology for patients with radically resected stage II and III colon cancerCATALANO, V; LOUPAKIS, F; FORNARO, L et al.Annals of oncology. 2012, Vol 23, Num 1, pp 135-141, issn 0923-7534, 7 p.Article

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerLOUPAKIS, F; CREMOLINI, C; DI PAOLO, A et al.British journal of cancer. 2011, Vol 104, Num 8, pp 1262-1269, issn 0007-0920, 8 p.Article

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patientsRONZONI, M; MANZONI, M; DANOVA, M et al.Annals of oncology. 2010, Vol 21, Num 12, pp 2382-2389, issn 0923-7534, 8 p.Article

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patientsALLEGRINI, G; FALCONE, A; DANESI, R et al.British journal of cancer. 2008, Vol 98, Num 8, pp 1312-1319, issn 0007-0920, 8 p.Article